IVERIC bio IncChange company Symbol lookupSelect an option...ISEE IVERIC bio IncHUN Huntsman CorpIART Integra Lifesciences Holdings CorpR Ryder System IncAAPL Apple IncIIM Invesco Value Municipal Income TrustQQQ Invesco QQQ TrustVZ Verizon Communications IncCHTR Charter Communications IncSPB Spectrum Brands Holdings IncGo
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.
|
|
|
|
| |
Company Profile
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- --
- Price/Book (MRQ)
- 5.44x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in thousands.
Income statement
Values displayed are in thousands.
Cash flow
Values displayed are in thousands.
Company Officers
- Adrienne L. Graves
- Pravin U. DugelPres.
- Glenn P. SblendorioCEO
- David Francis CarrollCFO
- Keith WestbyCOO
Address
- 8 Sylvan Way, Suite 2372
- Parsippany, NJ 07054
- Phone: (609) 474-6755
- Fax: (302) 655-5049
- https://ivericbio.com/
Insider Trading
During the most recent quarter, 25K shares were bought, and 272K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.